Taiwan
· Delayed Price · Currency is TWD OBI Pharma Statistics
Total Valuation
OBI Pharma has a market cap or net worth of TWD 16.30 billion. The enterprise value is 14.68 billion.
| Market Cap | 16.30B |
| Enterprise Value | 14.68B |
Important Dates
The last earnings date was Tuesday, March 25, 2025.
| Earnings Date | Mar 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OBI Pharma has 262.97 million shares outstanding. The number of shares has increased by 2.00% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 262.97M |
| Shares Change (YoY) | +2.00% |
| Shares Change (QoQ) | +7.70% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 5.16% |
| Float | 200.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 231.05 |
| PB Ratio | 4.00 |
| P/TBV Ratio | 4.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.36 |
| EV / Sales | 234.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.54 |
Financial Position
The company has a current ratio of 8.34, with a Debt / Equity ratio of 0.10.
| Current Ratio | 8.34 |
| Quick Ratio | 7.65 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.26 |
| Interest Coverage | -222.66 |
Financial Efficiency
Return on equity (ROE) is -51.01% and return on invested capital (ROIC) is -27.38%.
| Return on Equity (ROE) | -51.01% |
| Return on Assets (ROA) | -26.33% |
| Return on Invested Capital (ROIC) | -27.38% |
| Return on Capital Employed (ROCE) | -45.25% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | 5.18 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.93% in the last 52 weeks. The beta is 0.98, so OBI Pharma's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | -1.93% |
| 50-Day Moving Average | 59.16 |
| 200-Day Moving Average | 64.58 |
| Relative Strength Index (RSI) | 57.75 |
| Average Volume (20 Days) | 727,292 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OBI Pharma had revenue of TWD 62.68 million and -2.31 billion in losses. Loss per share was -9.89.
| Revenue | 62.68M |
| Gross Profit | -76.27M |
| Operating Income | -2.37B |
| Pretax Income | -2.50B |
| Net Income | -2.31B |
| EBITDA | -2.15B |
| EBIT | -2.37B |
| Loss Per Share | -9.89 |
Balance Sheet
The company has 3.13 billion in cash and 504.63 million in debt, giving a net cash position of 2.63 billion or 9.99 per share.
| Cash & Cash Equivalents | 3.13B |
| Total Debt | 504.63M |
| Net Cash | 2.63B |
| Net Cash Per Share | 9.99 |
| Equity (Book Value) | 4.82B |
| Book Value Per Share | 15.48 |
| Working Capital | 3.03B |
Cash Flow
In the last 12 months, operating cash flow was -1.83 billion and capital expenditures -113.24 million, giving a free cash flow of -1.95 billion.
| Operating Cash Flow | -1.83B |
| Capital Expenditures | -113.24M |
| Free Cash Flow | -1.95B |
| FCF Per Share | -7.40 |
Margins
| Gross Margin | -121.69% |
| Operating Margin | -3,783.67% |
| Pretax Margin | -3,982.59% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OBI Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.00% |
| Shareholder Yield | -2.00% |
| Earnings Yield | -14.17% |
| FCF Yield | -11.94% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |